Loan & DebtJul 6, 2026, 06:07 AM
BioXcel Therapeutics Amends Credit Agreement, Defers $9M Payment
AI Summary
BioXcel Therapeutics, Inc. entered into the Tenth Amendment to its Credit Agreement, deferring a $9.02 million principal and interest payment from June 30, 2026, to July 31, 2026. The amendment also reduced the minimum liquidity covenant to $7.5 million from $12.5 million. The company is now required to secure definitive agreements for full debt repayment or an alternative capital solution by July 31, 2026, and has established a Strategic Process Committee with broad authority over potential transactions. Additionally, the amendment imposes significant new reporting requirements and negative covenants, restricting various corporate actions and compensation changes.
Key Highlights
- Deferred $9,016,914.47 principal and interest payment from June 30, 2026, to July 31, 2026.
- Reduced minimum cash liquidity covenant from $12.5 million to $7.5 million.
- Required to enter definitive agreements for debt repayment or alternative capital by July 31, 2026.
- Established a Strategic Process Committee with exclusive authority over sales, restructuring, or other transactions.
- Agreed to additional reporting, including weekly meetings with lenders and bi-weekly cash flow budgets.
- Prohibited from making certain dividends, investments, asset disposals, or incurring new debt.
- Prohibited from modifying director/officer compensation or making non-ordinary course payments until July 31, 2026.
- Paid a 1.00% amendment fee, capitalized and added to outstanding principal.
Price Impact
More from BTAI